Kevin Wing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kevin Wing has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Laurie A. Tomlinson
Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
25 shared publications - Liam Smeeth
Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
25 shared publications - Angel Yun Sum Wong
Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London UK
24 shared publications - Anna Schultze
Department of Non‐communicable Disease Epidemiology London School of Hygiene & Tropical Medicine London UK
24 shared publications - Ian J. Douglas
Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
24 shared publications - Rohini Mathur
Affiliation Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom
24 shared publications
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Association Between Systemic Fluoroquinolones and Risk of Peripheral Neuropathy
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Association Between Systemic Fluoroquinolones and Risk of Peripheral Neuropathy
- 26 March 2026
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 80 (8) , 624-634
Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform
Background We aimed to explore the occurrence and persistence of symptoms, diagnoses and prescribing after COVID-19 among populations from earlier (wave 2) and later (wave 4) in the pandemic. Methods With the approval of NHS England, we analysed data from English primary care using The Phoenix Partnership SystmOne through the OpenSAFELY data analytics platform. Individuals with community-diagnosed COVID-19 September 2020–January 2021 (wave 2) were matched to contemporary (2020–2021) and historical (2017–2018) comparators. Individuals with community COVID-19 December 2021–March 2022 (wave 4) were matched to contemporary comparators (last follow-up 31 March 2023). Occurrence of each of (1) long-COVID symptoms; (2) primary-care diagnoses and (3) new prescriptions was analysed at any time during 1 year after COVID-19 and at: 4–12 weeks, 12 weeks–6 months and 6 months–12 months after COVID-19 to assess persistence. Results 902 885 COVID-19 cases (wave 2) matched to 4 449 265 contemporary (no-COVID-19) comparators. 1 553 160 COVID-19 cases (wave 4) matched to 7 624 770 contemporary comparators. Positive wave 2 associations after COVID-19 were observed for hair loss (OR 1.57, 95% CI 1.48 to 1.66), mobility impairment (1.41, 1.35 to 1.48), fatigue (1.46, 1.42 to 1.49), cognitive impairment (1.39, 1.34 to 1.44) and loss of taste or smell (1.38, 1.31 to 1.46). At 6–12 months reporting persisted for mobility impairment, fatigue and cognitive impairment. There were small increases in new prescriptions for NSAIDs (1.24, 1.23 to 1.26), drugs to treat infections (1.24, 1.23 to 1.25) and musculoskeletal problems (1.23, 1.22 to 1.25). Wave 4 associations were generally weaker than Wave 2. Conclusions Long-COVID symptoms and new prescribing generally reduce over time and are potentially less problematic following less severe illness. Fatigue/cognitive/mobility symptoms persist following COVID-19.
- 26 March 2026
- Published by BMJ in Journal of Epidemiology and Community Health
- Vol. 80 (8) , 624-634
Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform
Background We aimed to explore the occurrence and persistence of symptoms, diagnoses and prescribing after COVID-19 among populations from earlier (wave 2) and later (wave 4) in the pandemic. Methods With the approval of NHS England, we analysed data from English primary care using The Phoenix Partnership SystmOne through the OpenSAFELY data analytics platform. Individuals with community-diagnosed COVID-19 September 2020–January 2021 (wave 2) were matched to contemporary (2020–2021) and historical (2017–2018) comparators. Individuals with community COVID-19 December 2021–March 2022 (wave 4) were matched to contemporary comparators (last follow-up 31 March 2023). Occurrence of each of (1) long-COVID symptoms; (2) primary-care diagnoses and (3) new prescriptions was analysed at any time during 1 year after COVID-19 and at: 4–12 weeks, 12 weeks–6 months and 6 months–12 months after COVID-19 to assess persistence. Results 902 885 COVID-19 cases (wave 2) matched to 4 449 265 contemporary (no-COVID-19) comparators. 1 553 160 COVID-19 cases (wave 4) matched to 7 624 770 contemporary comparators. Positive wave 2 associations after COVID-19 were observed for hair loss (OR 1.57, 95% CI 1.48 to 1.66), mobility impairment (1.41, 1.35 to 1.48), fatigue (1.46, 1.42 to 1.49), cognitive impairment (1.39, 1.34 to 1.44) and loss of taste or smell (1.38, 1.31 to 1.46). At 6–12 months reporting persisted for mobility impairment, fatigue and cognitive impairment. There were small increases in new prescriptions for NSAIDs (1.24, 1.23 to 1.26), drugs to treat infections (1.24, 1.23 to 1.25) and musculoskeletal problems (1.23, 1.22 to 1.25). Wave 4 associations were generally weaker than Wave 2. Conclusions Long-COVID symptoms and new prescribing generally reduce over time and are potentially less problematic following less severe illness. Fatigue/cognitive/mobility symptoms persist following COVID-19.
- Open Access
- 16 September 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (9) , e1004465
Effectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data
Background: Guidelines by the National Institute for Health and Care Excellence recommend an angiotensin receptor blocker (ARB) rather than an angiotensin-converting enzyme inhibitor (ACEi) for the treatment of hypertension for people of African and Caribbean descent, due to an increased risk of angioedema associated with ACEi use observed in US trials. However, the effectiveness and risk of these drugs in Black populations in UK routine care is unknown. Methods and findings: We applied a reference trial emulation approach to UK Clinical Practice Research Datalink Aurum data (linked with data from Hospital Episode Statistics and Office for National Statistics) to study the comparative effectiveness of ARB and ACEi in ethnic minority groups in England, after benchmarking results against the ONTARGET trial. Approximately 17,593 Black, 30,805 South Asian, and 524,623 White patients receiving a prescription for ARB/ACEi between 1 January 2001 and 31 July 2019 were included with a median follow-up of 5.2 years. The primary composite outcome was cardiovascular-related death, myocardial infarction, stroke, or hospitalisation for heart failure with individual components studied as secondary outcomes. Angioedema was a safety endpoint. We assessed outcomes using an inverse-probability—weighted Cox proportional hazards model for ARB versus ACEi with heterogeneity by ethnicity assessed on the relative and absolute scale. For the primary outcome, 27,327 (18.0%) events were recorded in the ARB group (event rate: 25% per 5.5 person-years) and 80,624 (19.1%) events (event rate: 26% per 5.5 person-years) in the ACEi group. We benchmarked results against ONTARGET and observed hazard ratio (HR) 0.96 (95% CI: 0.95, 0.98) for the primary outcome, with an absolute incidence rate difference (IRD)% of -1.01 (95% CI: -1.42, -0.60) per 5.5 person-years. We found no evidence of treatment effect heterogeneity by ethnicity for the primary outcome on the multiplicative (Pint = 0.422) or additive scale (Pint = 0.287). Results were consistent for most secondary outcomes. However, for cardiovascular-related death, which occurred in 37,554 (6.6%) people, there was strong evidence of heterogeneity on the multiplicative (Pint = 0.002) and additive scale (Pint < 0.001). Compared to ACEi, ARB were associated with more events in Black individuals (HR 1.20 (95% CI: 1.02, 1.40); IRD% 1.07 (95% CI: 0.10, 2.04); number-needed-to-harm (NNH): 93) and associated with fewer events in White individuals (HR 0.91 (95% CI: 0.88, 0.93); IRD% -0.87 (95% CI: -1.10, -0.63); number-needed-to-treat (NNT): 115), and no differences in South Asian individuals (HR 0.97 (95% CI: 0.86, 1.09); IRD% -0.17 (95% CI: -0.87, 0.53)). For angioedema, HR 0.56 (95% CI: 0.46, 0.67) with no heterogeneity for ARB versus ACEi on the multiplicative scale (Pint = 0.306). However, there was heterogeneity on the additive scale (Pint = 0.023). Absolute risks were higher in Black individuals (IRD% -0.49 (95% CI: -0.79, -0.18); NNT: 204) compared with White individuals (IRD% -0.06 (95% CI: -0.09, -0.03); NNT: 1667) and no difference among South Asian individuals (IRD% -0.05 (95% CI: -0.15, 0.05) for ARB versus ACEi. Conclusions: These results demonstrate variation in drug effects of ACEi and ARB for some outcomes by ethnicity and suggest the potential for adverse consequences from current UK guideline recommendations for ARB in preference to ACEi for Black individuals.
- 16 September 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (9) , e1004465
Open AccessEffectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data
Background: Guidelines by the National Institute for Health and Care Excellence recommend an angiotensin receptor blocker (ARB) rather than an angiotensin-converting enzyme inhibitor (ACEi) for the treatment of hypertension for people of African and Caribbean descent, due to an increased risk of angioedema associated with ACEi use observed in US trials. However, the effectiveness and risk of these drugs in Black populations in UK routine care is unknown. Methods and findings: We applied a reference trial emulation approach to UK Clinical Practice Research Datalink Aurum data (linked with data from Hospital Episode Statistics and Office for National Statistics) to study the comparative effectiveness of ARB and ACEi in ethnic minority groups in England, after benchmarking results against the ONTARGET trial. Approximately 17,593 Black, 30,805 South Asian, and 524,623 White patients receiving a prescription for ARB/ACEi between 1 January 2001 and 31 July 2019 were included with a median follow-up of 5.2 years. The primary composite outcome was cardiovascular-related death, myocardial infarction, stroke, or hospitalisation for heart failure with individual components studied as secondary outcomes. Angioedema was a safety endpoint. We assessed outcomes using an inverse-probability—weighted Cox proportional hazards model for ARB versus ACEi with heterogeneity by ethnicity assessed on the relative and absolute scale. For the primary outcome, 27,327 (18.0%) events were recorded in the ARB group (event rate: 25% per 5.5 person-years) and 80,624 (19.1%) events (event rate: 26% per 5.5 person-years) in the ACEi group. We benchmarked results against ONTARGET and observed hazard ratio (HR) 0.96 (95% CI: 0.95, 0.98) for the primary outcome, with an absolute incidence rate difference (IRD)% of -1.01 (95% CI: -1.42, -0.60) per 5.5 person-years. We found no evidence of treatment effect heterogeneity by ethnicity for the primary outcome on the multiplicative (Pint = 0.422) or additive scale (Pint = 0.287). Results were consistent for most secondary outcomes. However, for cardiovascular-related death, which occurred in 37,554 (6.6%) people, there was strong evidence of heterogeneity on the multiplicative (Pint = 0.002) and additive scale (Pint < 0.001). Compared to ACEi, ARB were associated with more events in Black individuals (HR 1.20 (95% CI: 1.02, 1.40); IRD% 1.07 (95% CI: 0.10, 2.04); number-needed-to-harm (NNH): 93) and associated with fewer events in White individuals (HR 0.91 (95% CI: 0.88, 0.93); IRD% -0.87 (95% CI: -1.10, -0.63); number-needed-to-treat (NNT): 115), and no differences in South Asian individuals (HR 0.97 (95% CI: 0.86, 1.09); IRD% -0.17 (95% CI: -0.87, 0.53)). For angioedema, HR 0.56 (95% CI: 0.46, 0.67) with no heterogeneity for ARB versus ACEi on the multiplicative scale (Pint = 0.306). However, there was heterogeneity on the additive scale (Pint = 0.023). Absolute risks were higher in Black individuals (IRD% -0.49 (95% CI: -0.79, -0.18); NNT: 204) compared with White individuals (IRD% -0.06 (95% CI: -0.09, -0.03); NNT: 1667) and no difference among South Asian individuals (IRD% -0.05 (95% CI: -0.15, 0.05) for ARB versus ACEi. Conclusions: These results demonstrate variation in drug effects of ACEi and ARB for some outcomes by ethnicity and suggest the potential for adverse consequences from current UK guideline recommendations for ARB in preference to ACEi for Black individuals.
- 5 September 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (4) , 913-917
Improving the validity of noninterventional comparative effectiveness research by basing study design on a specified existing randomized controlled trial
This issue of the American Journal of Epidemiology includes 3 articles (2 reporting original analyses and 1 systematic review) in which noninterventional studies used an existing randomized controlled trial (RCT) as a reference standard to inform noninterventional study design and against which to benchmark results. This commentary provides a brief background on the challenges of noninterventional comparative effectiveness research, before elaborating on (1) the potential benefits and challenges of basing noninterventional study design on a specified existing RCT and (2) the distinction between designing analysis based upon a specified existing RCT and studies based solely upon a hypothetical target trial. Finally, several recommendations for the conduct and reporting of noninterventional studies based on existing RCTs are provided. This article is part of a Special Collection on Pharmacoepidemiology.
- 5 September 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (4) , 913-917
Improving the validity of noninterventional comparative effectiveness research by basing study design on a specified existing randomized controlled trial
This issue of the American Journal of Epidemiology includes 3 articles (2 reporting original analyses and 1 systematic review) in which noninterventional studies used an existing randomized controlled trial (RCT) as a reference standard to inform noninterventional study design and against which to benchmark results. This commentary provides a brief background on the challenges of noninterventional comparative effectiveness research, before elaborating on (1) the potential benefits and challenges of basing noninterventional study design on a specified existing RCT and (2) the distinction between designing analysis based upon a specified existing RCT and studies based solely upon a hypothetical target trial. Finally, several recommendations for the conduct and reporting of noninterventional studies based on existing RCTs are provided. This article is part of a Special Collection on Pharmacoepidemiology.
- Open Access
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (8) , e1004377
Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study
Background: Stroke prevention guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provide an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs; however, there remains uncertainty on the validity of methods and suitability of the data. Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in trials. We used linked United Kingdom primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban versus warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results. Methods and findings: Patients with AF in the UK Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 January 2013 to 31 July 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) TTR. The dataset comprised 8,734 apixaban users and propensity-score matched 8,734 warfarin users. Results [hazard ratio (95% confidence interval)] confirmed apixaban noninferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) versus trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year), whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year). Analysis by TTR suggested similar effectiveness of apixaban compared with poorly controlled warfarin (TTR < 0.75) for stroke/SE [0.91 (0.73, 1.14)], all-cause death [0.94 (0.84, 1.06)], and superiority for major bleeding [0.74 (0.63, 0.86)]. However, when compared with well-controlled warfarin (TTR ≥ 0.75), apixaban was associated with an increased hazard for all-cause death [1.20 (1.04, 1.37)], and there was no significant benefit for major bleeding [1.08 (0.90, 1.30)]. The main limitation of the study’s methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm, and selection bias and misclassification in the analysis by TTR. Conclusions: Analysis of noninterventional data generated results demonstrating noninferiority of apixaban versus warfarin consistent with prespecified benchmarking criteria. Unlike in ARISTOTLE, superiority of apixaban versus warfarin was not seen, possible due to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. This methodological template can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or underrepresented in trials and provides a framework that can be adapted to investigate treatment effects for other conditions.
- 29 August 2024
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 21 (8) , e1004377
Open AccessComparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study
Background: Stroke prevention guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provide an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs; however, there remains uncertainty on the validity of methods and suitability of the data. Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in trials. We used linked United Kingdom primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban versus warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results. Methods and findings: Patients with AF in the UK Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 January 2013 to 31 July 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) TTR. The dataset comprised 8,734 apixaban users and propensity-score matched 8,734 warfarin users. Results [hazard ratio (95% confidence interval)] confirmed apixaban noninferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) versus trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year), whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year). Analysis by TTR suggested similar effectiveness of apixaban compared with poorly controlled warfarin (TTR < 0.75) for stroke/SE [0.91 (0.73, 1.14)], all-cause death [0.94 (0.84, 1.06)], and superiority for major bleeding [0.74 (0.63, 0.86)]. However, when compared with well-controlled warfarin (TTR ≥ 0.75), apixaban was associated with an increased hazard for all-cause death [1.20 (1.04, 1.37)], and there was no significant benefit for major bleeding [1.08 (0.90, 1.30)]. The main limitation of the study’s methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm, and selection bias and misclassification in the analysis by TTR. Conclusions: Analysis of noninterventional data generated results demonstrating noninferiority of apixaban versus warfarin consistent with prespecified benchmarking criteria. Unlike in ARISTOTLE, superiority of apixaban versus warfarin was not seen, possible due to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. This methodological template can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or underrepresented in trials and provides a framework that can be adapted to investigate treatment effects for other conditions.
- Open Access
- 1 July 2024
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 142 (7) , 636-645
Systemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment
Importance: Fluoroquinolone use has been associated with increased risk of uveitis and retinal detachment in noninterventional studies, but the findings have been conflicting and causality is unclear.Objective: To estimate the association of systemic fluoroquinolone use with acute uveitis or retinal detachment, using multiple analyses and multiple databases to increase the robustness of results.Design, Setting, and Participants: This cohort study used data from the Clinical Practice Research Datalink Aurum and GOLD UK primary care records databases, which were linked to hospital admissions data. Adults prescribed a fluoroquinolone or a comparator antibiotic, cephalosporin, between April 1997 and December 2019 were included. Adults with uveitis or retinal detachment were analyzed in a separate self-controlled case series. Data analysis was performed from May 2022 to May 2023.Exposures: Systemic fluoroquinolone or comparator antibiotic.Main Outcomes and Measures: The primary outcome was a diagnosis of acute uveitis or retinal detachment. Hazard ratios (HRs) were estimated in the cohort study for the association of fluoroquinolone prescription with either uveitis or retinal detachment, using stabilized inverse probability of treatment weighted Cox regression. Rate ratios (RRs) were estimated in the self-controlled case series, using conditional Poisson regression. Estimates were pooled across databases using fixed-effects meta-analysis.Results: In total, 3 001 256 individuals in Aurum (1 893 561 women [63.1%]; median [IQR] age, 51 [35-68] years) and 434 754 in GOLD (276 259 women [63.5%]; median [IQR] age, 53 [37-70] years) were included in the cohort study. For uveitis, the pooled adjusted HRs (aHRs) for use of fluoroquinolone vs cephalosporin were 0.91 (95% CI, 0.72-1.14) at first treatment episode and 1.07 (95% CI, 0.92-1.25) over all treatment episodes. For retinal detachment, the pooled aHRs were 1.37 (95% CI, 0.80-2.36) at first treatment episode and 1.18 (95% CI, 0.84-1.65) over all treatment episodes. In the self-controlled case series, for uveitis, the pooled adjusted RRs (aRRs) for fluoroquinolone use vs nonuse were 1.13 (95% CI, 0.97-1.31) for 1 to 29 days of exposure, 1.16 (95% CI, 1.00-1.34) for 30 to 59 days, and 0.98 (95% CI, 0.74-1.31) for 60 days for longer. For retinal detachment, pooled aRRs for fluoroquinolone use vs nonuse were 1.15 (95% CI, 0.86-1.54) for 1 to 29 days of exposure, 0.94 (95% CI, 0.69-1.30) for 30 to 59 days, and 1.03 (95% CI, 0.59-1.78) for 60 days or longer.Conclusions and Relevance: These findings do not support an association of systemic fluoroquinolone use with substantively increased risk of uveitis or retinal detachment. Although an association cannot be completely ruled out, these findings indicate that any absolute increase in risk would be small and, hence, of limited clinical importance.
- 1 July 2024
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 142 (7) , 636-645
Open AccessSystemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment
Importance: Fluoroquinolone use has been associated with increased risk of uveitis and retinal detachment in noninterventional studies, but the findings have been conflicting and causality is unclear.Objective: To estimate the association of systemic fluoroquinolone use with acute uveitis or retinal detachment, using multiple analyses and multiple databases to increase the robustness of results.Design, Setting, and Participants: This cohort study used data from the Clinical Practice Research Datalink Aurum and GOLD UK primary care records databases, which were linked to hospital admissions data. Adults prescribed a fluoroquinolone or a comparator antibiotic, cephalosporin, between April 1997 and December 2019 were included. Adults with uveitis or retinal detachment were analyzed in a separate self-controlled case series. Data analysis was performed from May 2022 to May 2023.Exposures: Systemic fluoroquinolone or comparator antibiotic.Main Outcomes and Measures: The primary outcome was a diagnosis of acute uveitis or retinal detachment. Hazard ratios (HRs) were estimated in the cohort study for the association of fluoroquinolone prescription with either uveitis or retinal detachment, using stabilized inverse probability of treatment weighted Cox regression. Rate ratios (RRs) were estimated in the self-controlled case series, using conditional Poisson regression. Estimates were pooled across databases using fixed-effects meta-analysis.Results: In total, 3 001 256 individuals in Aurum (1 893 561 women [63.1%]; median [IQR] age, 51 [35-68] years) and 434 754 in GOLD (276 259 women [63.5%]; median [IQR] age, 53 [37-70] years) were included in the cohort study. For uveitis, the pooled adjusted HRs (aHRs) for use of fluoroquinolone vs cephalosporin were 0.91 (95% CI, 0.72-1.14) at first treatment episode and 1.07 (95% CI, 0.92-1.25) over all treatment episodes. For retinal detachment, the pooled aHRs were 1.37 (95% CI, 0.80-2.36) at first treatment episode and 1.18 (95% CI, 0.84-1.65) over all treatment episodes. In the self-controlled case series, for uveitis, the pooled adjusted RRs (aRRs) for fluoroquinolone use vs nonuse were 1.13 (95% CI, 0.97-1.31) for 1 to 29 days of exposure, 1.16 (95% CI, 1.00-1.34) for 30 to 59 days, and 0.98 (95% CI, 0.74-1.31) for 60 days for longer. For retinal detachment, pooled aRRs for fluoroquinolone use vs nonuse were 1.15 (95% CI, 0.86-1.54) for 1 to 29 days of exposure, 0.94 (95% CI, 0.69-1.30) for 30 to 59 days, and 1.03 (95% CI, 0.59-1.78) for 60 days or longer.Conclusions and Relevance: These findings do not support an association of systemic fluoroquinolone use with substantively increased risk of uveitis or retinal detachment. Although an association cannot be completely ruled out, these findings indicate that any absolute increase in risk would be small and, hence, of limited clinical importance.
- Open Access
- 18 June 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (12) , 1785-1795
Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
Cardiovascular disease (CVD) is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial, each prevent CVD. However, trial results may not be generalisable and their effectiveness in underrepresented groups is unclear. Using trial emulation methods within routine-care data to validate findings, we explored generalisability of ONTARGET results. For people prescribed an ACEi/ARB in the UK Clinical Practice Research Datalink GOLD from 1/1/2001-31/7/2019, we applied trial criteria and propensity-score methods to create an ONTARGET trial-eligible cohort. Comparing ARB to ACEi, we estimated hazard ratios for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure), and secondary outcomes. As the pre-specified criteria were met confirming trial emulation, we then explored treatment heterogeneity among three trial-underrepresented subgroups: females, those aged ≥75 years and those with chronic kidney disease (CKD). In the trial-eligible population (n=137,155), results for the primary outcome demonstrated similar effects of ARB and ACEi, (HR 0.97 [95% CI: 0.93, 1.01]), meeting the pre-specified validation criteria. When extending this outcome to trial-underrepresented groups, similar treatment effects were observed by sex, age and CKD. This suggests that ONTARGET trial findings are generalisable to trial-underrepresented subgroups.
- 18 June 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 193 (12) , 1785-1795
Open AccessCardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
Cardiovascular disease (CVD) is a leading cause of death globally. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), compared in the ONTARGET trial, each prevent CVD. However, trial results may not be generalisable and their effectiveness in underrepresented groups is unclear. Using trial emulation methods within routine-care data to validate findings, we explored generalisability of ONTARGET results. For people prescribed an ACEi/ARB in the UK Clinical Practice Research Datalink GOLD from 1/1/2001-31/7/2019, we applied trial criteria and propensity-score methods to create an ONTARGET trial-eligible cohort. Comparing ARB to ACEi, we estimated hazard ratios for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure), and secondary outcomes. As the pre-specified criteria were met confirming trial emulation, we then explored treatment heterogeneity among three trial-underrepresented subgroups: females, those aged ≥75 years and those with chronic kidney disease (CKD). In the trial-eligible population (n=137,155), results for the primary outcome demonstrated similar effects of ARB and ACEi, (HR 0.97 [95% CI: 0.93, 1.01]), meeting the pre-specified validation criteria. When extending this outcome to trial-underrepresented groups, similar treatment effects were observed by sex, age and CKD. This suggests that ONTARGET trial findings are generalisable to trial-underrepresented subgroups.
- Open Access
Cardiorenal effects of dual blockade with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people with CKD: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
We aimed to explore whether the ONTARGET trial results, which led to an end of recommendations of dual angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) use, extended to patients with chronic kidney disease (CKD) who were underrepresented in the trial. We selected people prescribed an ACEi and/or an ARB in the UK Clinical Practice Research Datalink Aurum during 1/1/2001-31/7/2019. We specified an operational definition of dual users and applied ONTARGET eligibility criteria. We used propensity-score—weighted Cox-proportional hazards models to compare dual therapy to ACEi for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure), as well as a primary composite renal outcome (≥50% reduction in GFR or end-stage kidney disease), and other secondary outcomes, including hyperkalaemia. Conditional on successfully benchmarking results against the ONTARGET trial, we explored treatment effect heterogeneity by CKD at baseline. In the propensity-score—weighted trial-eligible analysis cohort (n=412 406), for dual therapy vs ACEi we observed hazard ratio (HR) 0.98 (95% CI: 0.93, 1.03), for the primary composite outcome, consistent with the trial results (ONTARGET HR 0.99, 95% CI: 0.92, 1.07). Dual therapy use was associated with an increased risk of the primary renal composite outcome, HR 1.25 (95% CI: 1.15, 1.36) vs ONTARGET HR 1.24 (1.01, 1.51) and hyperkalaemia, HR 1.15 (95% CI: 1.09, 1.22) in the trial eligible cohort, consistent with ONTARGET. The presence of CKD at baseline had minimal impact on results. Translational statement: We extended ONTARGET trial findings of the comparative effectiveness of dual ARB and ACEi therapy use compared to ACEi alone for a composite cardiovascular outcome to UK patients at high-risk of cardiovascular disease, including those with CKD. As in ONTARGET, we found an increased risk of a composite renal outcome (≥50% reduction in GFR or end-stage kidney disease) and an increased risk of hyperkalaemia among dual users compared to ACEi alone. Consistent results were observed among patients with CKD at baseline. This is evidence against the hypothesis that dual blockade provides cardiorenal benefits among high-risk cardiovascular patients with CKD.
Open AccessCardiorenal effects of dual blockade with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people with CKD: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
We aimed to explore whether the ONTARGET trial results, which led to an end of recommendations of dual angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) use, extended to patients with chronic kidney disease (CKD) who were underrepresented in the trial. We selected people prescribed an ACEi and/or an ARB in the UK Clinical Practice Research Datalink Aurum during 1/1/2001-31/7/2019. We specified an operational definition of dual users and applied ONTARGET eligibility criteria. We used propensity-score—weighted Cox-proportional hazards models to compare dual therapy to ACEi for the primary composite trial outcome (cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure), as well as a primary composite renal outcome (≥50% reduction in GFR or end-stage kidney disease), and other secondary outcomes, including hyperkalaemia. Conditional on successfully benchmarking results against the ONTARGET trial, we explored treatment effect heterogeneity by CKD at baseline. In the propensity-score—weighted trial-eligible analysis cohort (n=412 406), for dual therapy vs ACEi we observed hazard ratio (HR) 0.98 (95% CI: 0.93, 1.03), for the primary composite outcome, consistent with the trial results (ONTARGET HR 0.99, 95% CI: 0.92, 1.07). Dual therapy use was associated with an increased risk of the primary renal composite outcome, HR 1.25 (95% CI: 1.15, 1.36) vs ONTARGET HR 1.24 (1.01, 1.51) and hyperkalaemia, HR 1.15 (95% CI: 1.09, 1.22) in the trial eligible cohort, consistent with ONTARGET. The presence of CKD at baseline had minimal impact on results. Translational statement: We extended ONTARGET trial findings of the comparative effectiveness of dual ARB and ACEi therapy use compared to ACEi alone for a composite cardiovascular outcome to UK patients at high-risk of cardiovascular disease, including those with CKD. As in ONTARGET, we found an increased risk of a composite renal outcome (≥50% reduction in GFR or end-stage kidney disease) and an increased risk of hyperkalaemia among dual users compared to ACEi alone. Consistent results were observed among patients with CKD at baseline. This is evidence against the hypothesis that dual blockade provides cardiorenal benefits among high-risk cardiovascular patients with CKD.
- Open Access
Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK Clinical Practice Research Datalink Aurum: A reference trial (ARISTOTLE) emulation study
Background: Stroke prevention treatment guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provides an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs, however there remains uncertainty on the validity of the methods and suitability of the data. Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in the original trials. We used linked UK primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban vs warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results. Methods and findings: Patients with AF in a UK primary care database Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 Jan 2013 to 31 Jul 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) time in therapeutic range (TTR). The analysis sample comprised 8734 apixaban users and propensity-score matched 8734 warfarin users in CPRD. Results [Hazard Ratio (95% Confidence Interval)] confirmed apixaban non-inferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) vs trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) vs trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for Stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year) whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year) Analysis by TTR suggested non-inferiority of apixaban in those with TTR < 0.75 [Stroke/SE 0.94 (0.75,1.19), all-cause death 0.99 (0.87,1.12)]. However, apixaban was associated with increased hazards compared with well-controlled warfarin treatment (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), all-cause death 1.75 (1.49,2.06)]. The main limitation of the study’s methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm. Conclusions: Analysis of non-interventional data generated results demonstrating non-inferiority of apixaban vs warfarin consistent with the pre-specified benchmarking criteria. Unlike in ARISTOTLE superiority of apixaban vs warfarin was not seen which may be linked to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. The methodological template developed can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or under-represented in trials and also provides a framework which can be adapted to investigate treatment effects for other conditions. AUTHOR SUMMARY: Why Was This Study Done?: Stroke prevention treatment guidelines for patients with atrial fibrillation (AF) are based on results from randomised controlled trials (RCTs), we do not know if these results are relevant to patients that would not have been eligible to be included in the RCTs. This study used routinely collected health data from the UK to emulate an RCT that compared apixaban to warfarin, ARISTOTLE, and also looked at whether the benefit of apixban compared with warfarin was impacted by the quality of warfarin therapy (measured by time in therapeutic range, TTR). Emulating an RCT for stroke prevention in patients with AF should help to understand how transferable RCT results are to ‘real-world’ practices and whether this methodological approach can help to improve treatment options and outcomes for patient groups currently underrepresented in clinical trials. What Did the Researchers Do and Find?: The researchers looked at patients with AF in a UK primary care data prescribed apixaban or warfarin and applied a “reference trial emulation” approach, in which the ARISTOTLE trial eligibility, selection and analysis approaches were applied to UK primary care data and results benchmarked against those of ARISTOTLE. Patients prescribed apixaban had similar rates of outcomes to those prescribed warfarin in our cohort and our results were successfully benchmarked against ARISTOTLE. Unlike ARISTOTLE we did not see superiority of apixaban vs warfarin [Hazard ratio (95% confidence interval)] for time to stroke or systemic embolism: 0.98 (0.82,1.19) in our cohort vs 0.79 (0.66,0.95) in ARISTOTLE. We also found the benefit of apixaban vs warfarin differed depending on the quality of warfarin therapy with apixaban superior to poorly controlled warfarin therapy (TTR < 0.75) [Stroke/SE 0.94 (0.75,1.19), Death 0.99 (0.87,1.12)] whereas apixaban was not superior to well-controlled warfarin (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), Death 1.75 (1.49,2.06)]. What Do These Findings Mean?: ur results support the NICE guidelines on selecting treatment for stroke prevention in patients with AF and also provide reassurance on continuing warfarin in patients with high TTR. can use UK primary health care data to emulate a reference trial of treatments for the prevention of stroke in AF. can use the data and methods to look at how well treatments work in patients that would not have been included in RCTs such as those with multimorbidity or patient groups under-represented in RCTs such as ethnic...
Open AccessComparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK Clinical Practice Research Datalink Aurum: A reference trial (ARISTOTLE) emulation study
Background: Stroke prevention treatment guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provides an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs, however there remains uncertainty on the validity of the methods and suitability of the data. Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in the original trials. We used linked UK primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban vs warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results. Methods and findings: Patients with AF in a UK primary care database Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 Jan 2013 to 31 Jul 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) time in therapeutic range (TTR). The analysis sample comprised 8734 apixaban users and propensity-score matched 8734 warfarin users in CPRD. Results [Hazard Ratio (95% Confidence Interval)] confirmed apixaban non-inferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) vs trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) vs trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for Stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year) whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year) Analysis by TTR suggested non-inferiority of apixaban in those with TTR < 0.75 [Stroke/SE 0.94 (0.75,1.19), all-cause death 0.99 (0.87,1.12)]. However, apixaban was associated with increased hazards compared with well-controlled warfarin treatment (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), all-cause death 1.75 (1.49,2.06)]. The main limitation of the study’s methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm. Conclusions: Analysis of non-interventional data generated results demonstrating non-inferiority of apixaban vs warfarin consistent with the pre-specified benchmarking criteria. Unlike in ARISTOTLE superiority of apixaban vs warfarin was not seen which may be linked to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. The methodological template developed can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or under-represented in trials and also provides a framework which can be adapted to investigate treatment effects for other conditions. AUTHOR SUMMARY: Why Was This Study Done?: Stroke prevention treatment guidelines for patients with atrial fibrillation (AF) are based on results from randomised controlled trials (RCTs), we do not know if these results are relevant to patients that would not have been eligible to be included in the RCTs. This study used routinely collected health data from the UK to emulate an RCT that compared apixaban to warfarin, ARISTOTLE, and also looked at whether the benefit of apixban compared with warfarin was impacted by the quality of warfarin therapy (measured by time in therapeutic range, TTR). Emulating an RCT for stroke prevention in patients with AF should help to understand how transferable RCT results are to ‘real-world’ practices and whether this methodological approach can help to improve treatment options and outcomes for patient groups currently underrepresented in clinical trials. What Did the Researchers Do and Find?: The researchers looked at patients with AF in a UK primary care data prescribed apixaban or warfarin and applied a “reference trial emulation” approach, in which the ARISTOTLE trial eligibility, selection and analysis approaches were applied to UK primary care data and results benchmarked against those of ARISTOTLE. Patients prescribed apixaban had similar rates of outcomes to those prescribed warfarin in our cohort and our results were successfully benchmarked against ARISTOTLE. Unlike ARISTOTLE we did not see superiority of apixaban vs warfarin [Hazard ratio (95% confidence interval)] for time to stroke or systemic embolism: 0.98 (0.82,1.19) in our cohort vs 0.79 (0.66,0.95) in ARISTOTLE. We also found the benefit of apixaban vs warfarin differed depending on the quality of warfarin therapy with apixaban superior to poorly controlled warfarin therapy (TTR < 0.75) [Stroke/SE 0.94 (0.75,1.19), Death 0.99 (0.87,1.12)] whereas apixaban was not superior to well-controlled warfarin (TTR ≥ 0.75) [Stroke/SE 1.49 (1.13,1.97), Death 1.75 (1.49,2.06)]. What Do These Findings Mean?: ur results support the NICE guidelines on selecting treatment for stroke prevention in patients with AF and also provide reassurance on continuing warfarin in patients with high TTR. can use UK primary health care data to emulate a reference trial of treatments for the prevention of stroke in AF. can use the data and methods to look at how well treatments work in patients that would not have been included in RCTs such as those with multimorbidity or patient groups under-represented in RCTs such as ethnic...
- Open Access
- 1 February 2024
- Published by Center for Open Science in OSF Preprints
Reference Trial Emulation to Improve the Validity of Non-Interventional Comparative Effectiveness Research
In this commentary we discuss use of the “reference trial emulation” approach in non-interventional comparative effectiveness research, in which an existing randomized controlled trial (RCT) is used as a reference standard to both inform the design of a non-interventional study, and for the benchmarking of the non-interventional analysis results. We provide a brief background on the challenges of non-interventional comparative effectiveness research, before elaborating on (i) what a reference trial is (ii) the potential benefits and pitfalls of reference trial emulation and (iii) how reference trial emulation relates to target trial emulation. Finally, a number of recommendations for the conduct and reporting of reference trial emulations are provided.
- 1 February 2024
- Published by Center for Open Science in OSF Preprints
Open AccessReference Trial Emulation to Improve the Validity of Non-Interventional Comparative Effectiveness Research
In this commentary we discuss use of the “reference trial emulation” approach in non-interventional comparative effectiveness research, in which an existing randomized controlled trial (RCT) is used as a reference standard to both inform the design of a non-interventional study, and for the benchmarking of the non-interventional analysis results. We provide a brief background on the challenges of non-interventional comparative effectiveness research, before elaborating on (i) what a reference trial is (ii) the potential benefits and pitfalls of reference trial emulation and (iii) how reference trial emulation relates to target trial emulation. Finally, a number of recommendations for the conduct and reporting of reference trial emulations are provided.